A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease
Paulo Fontoura(Roche (Switzerland)), Mirjana Andjelković(Roche (Switzerland)), Ernest Dorflinger(Amsterdam UMC Location Vrije Universiteit Amsterdam), Kaj Blennow(Sahlgrenska University Hospital), Philip Scheltens(Amsterdam University Medical Centers), Luca Santarelli(Roche (Switzerland)), Paul Delmar(Roche (Switzerland)), Elizabeth Ashford(Roche (Switzerland)), Merçé Boada(Instituto de Salud Carlos III), Sylvie Retout(Roche (Switzerland)), Carsten Hofmann(Roche (Switzerland)), Frederik Barkhof(National Hospital for Neurology and Neurosurgery), Robert Lasser(Takeda (United States)), Tania Nikolcheva(Roche (Switzerland)), Gregory Klein(Roche (Switzerland)), Susanne Ostrowitzki, Bruno Dubois(Portland State University)
Cited by 568
Related Papers
The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
|Alzheimer s & Dementia|2011|18.9k
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
|Alzheimer s & Dementia|2018|10.4k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration
|The Lancet Neurology|2013|5.4k
Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment
|Journal of Internal Medicine|2004|5k